Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 12:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 2,387 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Progressive Clear all
Terminated Phase 2 Interventional Results available

A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)

NCT04504916
View directory record Official record
Conditions
Triple-negative Breast Cancer, Non-squamous Non-small-cell Lung Cancer, NSCLC, Estrogen-receptor-positive Breast Cancer, Progesterone-receptor-positive Breast Cancer, Estrogen-receptor-negative Breast Cancer, ER-negative Breast Cancer, Progesterone-receptor Negative Breast Cancer, PR-negative Breast Cancer, HER2-negative Breast Cancer, ER-positive Breast Cancer, PR-positive Breast Cancer, Platinum-resistant Ovarian Cancer, Gastric Cancer, Pancreatic Cancer
Interventions
Zilovertamab vedotin
Drug
Lead sponsor
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
8
States / cities
Hollywood, Florida • Orlando, Florida • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 28, 2026, 12:36 AM EDT
Completed Phase 3 Interventional Results available

First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin

NCT00981058
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Necitumumab, Gemcitabine, Cisplatin
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,093 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2024
U.S. locations
15
States / cities
Chandler, Arizona • Fayetteville, Arkansas • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 28, 2026, 12:36 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)

NCT03713593
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
lenvatinib, pembrolizumab, saline placebo
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
794 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
21
States / cities
Tucson, Arizona • Duarte, California • La Jolla, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 28, 2026, 12:36 AM EDT
Completed Phase 1Phase 2 Interventional Results available

AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer

NCT01233687
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
AMG 102 and erlotinib
Drug
Lead sponsor
Ahmad Tarhini
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Oct 28, 2026, 12:36 AM EDT
Completed Phase 1Phase 2 Interventional

A Phase I/II Study With CEA(6D) VRP Vaccine in Patients With Advanced or Metastatic CEA-Expressing Malignancies

NCT00529984
View directory record Official record
Conditions
Colorectal Cancer, Breast Cancer, Lung Cancer, Pancreatic Cancer, Colon Cancer
Interventions
AVX701
Biological
Lead sponsor
AlphaVax, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 12, 2012 · Synced Oct 28, 2026, 12:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Fall Recovery Training for Older Adults in Continuous Care Facilities

NCT02173015
View directory record Official record
Conditions
Accidental Falls
Interventions
Compensatory step training
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 28, 2026, 12:36 AM EDT
Terminated Phase 2 Interventional Results available

Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma

NCT05117008
View directory record Official record
Conditions
Refractory Multiple Myeloma, Relapse Multiple Myeloma
Interventions
Belantamab mafodotin
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 28, 2026, 12:36 AM EDT
Recruiting Phase 2 Interventional

A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer

NCT05534438
View directory record Official record
Conditions
Oligometastatic Breast Carcinoma, Breast Cancer, Metastatic Breast Cancer, Metastatic Breast Carcinoma, ER+ Breast Cancer, HER2+ Breast Cancer
Interventions
Stereotactic body radiotherapy
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 28, 2026, 12:36 AM EDT
Terminated Phase 1Phase 2 Interventional

A Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Subjects With Recurrent GBM

NCT05370508
View directory record Official record
Conditions
Recurrent GBM
Interventions
SONALA-001 (ALA) and MR-Guided Focused Ultrasound device (MRgFUS)
Combination Product
Lead sponsor
SonALAsense, Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
6
States / cities
Phoenix, Arizona • San Francisco, California • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2024 · Synced Oct 28, 2026, 12:36 AM EDT
Recruiting Not applicable Interventional

Nutrition and Exercise Interventions for Androgen Deprivation Therapy-Induced Obese Frailty in Elderly and Non-Elderly Survivors of Advanced Prostate Cancer

NCT03880422
View directory record Official record
Conditions
Cancer Survivor, Obesity, Overweight, Prostate Adenocarcinoma, Stage A Prostate Cancer, Stage B Prostate Cancer, Stage C Prostate Cancer, Stage D Prostate Cancer, Stage I Prostate Cancer, Stage II Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage IIC Prostate Cancer, Stage III Prostate Cancer, Stage IIIA Prostate Cancer, Stage IIIB Prostate Cancer, Stage IIIC Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer
Interventions
Dietary Intervention, Educational Intervention, Exercise Intervention, Quality-of-Life Assessment, Survey Administration
Dietary Supplement · Other · Behavioral
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 28, 2026, 12:36 AM EDT
Completed No phase listed Observational

S9007, Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers

NCT00996047
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
cytogenetic analysis, fluorescence in situ hybridization
Genetic
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
3,341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2012
U.S. locations
280
States / cities
Mobile, Alabama • Anchorage, Alaska • Tucson, Arizona + 182 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 28, 2026, 12:36 AM EDT
Completed Phase 2 Interventional Results available

A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer

NCT00913835
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
Olaratumab, liposomal doxorubicin
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
6
States / cities
Joliet, Illinois • Indianapolis, Indiana • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Oct 28, 2026, 12:36 AM EDT
Completed Phase 2 Interventional Results available

Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma

NCT00795665
View directory record Official record
Conditions
Glioma
Interventions
bevacizumab, carmustine
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Oct 28, 2026, 12:36 AM EDT
Not yet recruiting Not applicable Interventional

Using a Primary Care- Based Stepped-Care Model of Trauma Focused Cognitive Behavioral Therapy (PSC-TF-CBT)to Reduce Trauma Symptoms and Negative Mental Health Sequelae

NCT07797400
View directory record Official record
Conditions
Trauma Patients
Interventions
PSC-TF-CBT
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
8 Years to 14 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 28, 2026, 12:36 AM EDT
Recruiting Phase 1 Interventional

Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas

NCT07544992
View directory record Official record
Conditions
Recurrent Astrocytoma, IDH-Mutant, Grade 4, Recurrent Glioblastoma, IDH-Wildtype
Interventions
Autologous Anti-EGFR/Anti-IL13Ralpha2 CAR T-cells, Biopsy Procedure, Biospecimen Collection, Echocardiography Test, FDG-Positron Emission Tomography, Intracranial Catheter Placement, Leukapheresis, Magnetic Resonance Imaging, Resection
Biological · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 28, 2026, 12:36 AM EDT
Completed Phase 3 Interventional Results available

Heartland Osteoporosis Prevention Study

NCT02186600
View directory record Official record
Conditions
Osteopenia
Interventions
Calcium Carbonate, Vitamin D3, Risedronate, Bone-loading exercises
Drug · Behavioral
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older · Female only
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 28, 2026, 12:36 AM EDT
Completed Not applicable Interventional Results available

Trial Comparing the Effects of Linear Versus Nonlinear Aerobic Training in Women With Operable Breast Cancer

NCT01186367
View directory record Official record
Conditions
Breast Cancer
Interventions
Linear Aerobic Training, Nonlinear Aerobic Training, Progressive Stretching, Cardiopulmonary exercise test (CPET), Blood draws
Behavioral · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
45 Years to 80 Years · Female only
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 28, 2026, 12:36 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Climbing Lifestyle Intervention for Modifying Physical Activity Behaviors: Pilot Study

NCT06368128
View directory record Official record
Conditions
Lifestyle Factors, Physical Inactivity, Quality of Life
Interventions
Indoor Rock Climbing Exercise Training Program
Behavioral
Lead sponsor
Northern Michigan University
Other
Eligibility
18 Years to 35 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Marquette, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced Oct 28, 2026, 12:36 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Strength Training and Resveratrol

NCT06585865
View directory record Official record
Conditions
Sarcopenia, Anabolic Resistance
Interventions
Resistance training, Resveratrol 500 mg oral once daily., Placebo
Behavioral · Dietary Supplement
Lead sponsor
Texas Tech University
Other
Eligibility
60 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 28, 2026, 12:36 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide

NCT01432600
View directory record Official record
Conditions
Myeloma
Interventions
Pomalidomide, Dexamethasone, Cyclophosphamide
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
3
States / cities
San Francisco, California • Tampa, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Oct 28, 2026, 12:36 AM EDT
Completed Phase 1 Interventional

AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors

NCT00326664
View directory record Official record
Conditions
Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Germ Cell Tumor, Childhood Cerebral Anaplastic Astrocytoma, Childhood Cerebral Astrocytoma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood Infratentorial Ependymoma, Childhood Oligodendroglioma, Childhood Spinal Cord Neoplasm, Childhood Supratentorial Ependymoma, Recurrent Childhood Brain Neoplasm, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Subependymal Giant Cell Astrocytoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway Glioma
Interventions
Cediranib Maleate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
11
States / cities
San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2016 · Synced Oct 28, 2026, 12:36 AM EDT
Completed Phase 2 Interventional Results available

Ph II Gemcitabine, Erlotinib, and Gemcitabine With Erlotinib/Elderly Patients W/ IIIB/IV NSCLC

NCT00283244
View directory record Official record
Conditions
Lung Cancer
Interventions
erlotinib hydrochloride, gemcitabine hydrochloride
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
70 Years to 120 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
11
States / cities
Fayetteville, Arkansas • Savannah, Georgia • Evanston, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Oct 28, 2026, 12:36 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

NEAT!2 Sedentary Behavior Reduction for Individuals With Past or Present Knee Symptoms, Injuries, or Surgeries

NCT03987932
View directory record Official record
Conditions
Sedentary Lifestyle, Knee Osteoarthritis, Knee Injuries, Knee Pain Chronic
Interventions
NEAT!2, NEAT!2+Calls, Delayed NEAT!2
Behavioral
Lead sponsor
University of South Carolina
Other
Eligibility
40 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Oct 28, 2026, 12:36 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Effects of Nicotine Replacement Therapy and D-cycloserine on Nicotine Treatment Seekers

NCT01907594
View directory record Official record
Conditions
Cigarette Smoking
Interventions
D-cycloserine, Nicotine Replacement Therapy (patch), Smoking Cue Exposure, Progressive Muscle Relaxation, Placebo
Drug · Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 28, 2026, 12:36 AM EDT